Skip to main content
Glycorex Transplantation AB logo

Glycorex Transplantation AB — Investor Relations & Filings

Ticker · GTAB ISIN · SE0000524530 LEI · 549300BFHBYZ3X96EP25 NGM Manufacturing
Open in API
Filings indexed 97 across all filing types
Latest filing 2026-05-22 Interim / Quarterly Rep…
Country SE Sweden
Listing NGM GTAB

About Glycorex Transplantation AB

https://glycorex.com/

Glycorex Transplantation AB is a medical technology company that has developed a proprietary technology platform for the specific removal of antibodies from blood. The technology is based on biologically active carbohydrates for extracorporeal blood treatment. Its flagship product, Glycosorb® ABO, is a single-use medical device that enables organ transplantation across the blood group barrier, primarily for kidney, liver, heart, and stem cell transplants. Used clinically since 2001, the product has facilitated over 6,000 ABO-incompatible transplants with documented long-term results comparable to blood group compatible procedures. The company is leveraging its core technology to expand into new applications, including a product for creating universal blood plasma for transfusions and developing novel treatments for autoimmune diseases, with an initial focus on rheumatoid arthritis.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is a detailed interim report (“Delårsrapport Q1 2026”) containing actual Q1 financial statements (net revenue, operating results, tables) and narrative analysis (CEO comments, segment performance, strategy). It is not merely an announcement or a presentation but the substantive quarterly financial report itself. Therefore, it should be classified as an Interim / Quarterly Report. Q1 2026
2026-05-22 Swedish
Glycorex Transplantation AB utser Carl-Magnus Högerkorp till ny VD
Board/Management Information Classification · 100% confidence The document announces the appointment of a new CEO (Carl-Magnus Högerkorp) for Glycorex Transplantation AB, including his background and the company's business focus. There is no financial data, no report or presentation attached, and the content is clearly about a management change. The document is short (3886 characters) and is a straightforward announcement of a change in senior management. Therefore, it fits the category of Board/Management Information (MANG).
2026-05-08 English
Glycorex Transplantation (GTAB B): Kallelse till årsstämma 4 juni 2026
AGM Information Classification · 95% confidence The document is a notice calling shareholders to the Annual General Meeting (AGM) of Glycorex Transplantation AB, scheduled for June 4, 2026. It includes details about the meeting agenda such as approval of financial statements, decisions on profit allocation, discharge of liability, remuneration, election of board and auditors, and authorization for share issuance. The document is relatively short (3082 characters) and serves as an invitation and agenda notice rather than the actual meeting materials or reports. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices related to it. It is not an Annual Report or any other financial report, nor is it a report publication announcement since it contains substantive meeting information. Therefore, the correct classification is AGM Information (AGM-R).
2026-05-05 English
Annual Report 2025
Annual Report Classification · 100% confidence The document is titled 'Årsredovisning 2025' which translates to 'Annual Report 2025' in English. It contains detailed financial statements such as income statements, balance sheets, cash flow statements for both the group and the parent company, notes, management commentary (VD-ord), and other comprehensive information typical of a full annual report. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes financial performance, business overview, strategy, and governance information, all consistent with an Annual Report (10-K equivalent). There is no indication that this is merely an announcement or a certification document, so it should not be classified as RPA or RNS. Therefore, the correct classification is Annual Report (10-K). FY 2025
2026-04-30 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport' (Interim Report) for Glycorex Transplantation AB for the period January-September 2025. It contains detailed financial statements (income statement, balance sheet data), management commentary (Vd-ord), and operational updates. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2025
2025-11-28 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport' (Interim Report) for Glycorex Transplantation AB for the period January-June 2025. It contains comprehensive financial statements, including income statements, balance sheet data, and management commentary (Vd-ord). It is a formal financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2025
2025-08-29 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.